|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Safety, tolerability, phar- macodynamics, and pharmacokinetics of rivaroxaban-an oral, di- rect Factor Xa inhibitor-are not affected by aspirin 显示文摘 | Kubitza D Becka M Mueck W | 2006 | J Clin Pharmacol2006，46，9： | 1 |
| 2 | No interaction between the novel oral direct factor Xa inhibitor BAY 59-7939 and digoxin 显示文摘 | Kubitza D Mueck W Becka M | 2006 | J Clin Phann2006，46，3： | 1 |
| 3 | Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral direct factor Xa inhibitor in healthy subjects显示文摘 | Mueck W Beeka M Kubitza D | | 0，，： | 1 |
| 4 | A survey of visual impairment and blindness in children attending seven schools for the blind in Myanmar显示文摘 | Muecke J Hammerton M Aung YY | 2009 | Ophthalmic Epidemiol2009，16，6： | 1 |
| 5 | In vitro evaluation of magnetic resonance imaging contrast agents for labeling human liver ceils: implica- tions for clinical translation 显示文摘 | RASCHZOK N MUECKE D A ADONOPOULOU M K | 2010 | Mol Imaging Biol2010，13，4： | 1 |
| 6 | Significance of Europium anomalies in silicate melts and crystal-melt equilibria: a re-evaluation显示文摘 | P. M?ller G. K. Muecke | 1984 | Contributions to Mineralogy and Petrology1984，，3： | 1 |
| 7 | Safety, tolerabil- ity, pharmacodynamics, and pharmacokinetics of rivaroxa- ban--an oral, direct factor Xa inhibitor--are not affected by aspirin 显示文摘 | KUBITZA D BECKA M MUECK W | 2006 | J Clin Pharmacol2006，46，9： | 1 |
| 8 | Austrian Moder- ate Altitude Studies (AMAS): benefits of exposure to moderate alti- tudes (1,500-2,500 m) 显示文摘 | Schobersberger W Leichtfried V Mueck M | 2010 | Sleep Breath2010，14，3： | 1 |
| 9 | Further evidence for direct vascular actions of statins: effect on endothelial nitric oxide synthase and adhesion molecules 显示文摘 | Mueck AO Seeger H Risch M | 2001 | Exp Clin Endocrinol Diabetes2001，，： | 1 |
| 10 | Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban -- an oral direct factor Xa inhibitor -- in healthy subjects 显示文摘 | Mueck W Becka M Kubitza D | 2007 | Int J Clin Pharmacol Ther2007，45，33： | 1 |
| 11 | Rivaroxaban(BAY 59-7939)-an oral,direct Factor Xa inhibitor-has no clinically relevant interaction with naproxen 显示文摘 | Kubitza D Becka M Mueck W | 2007 | Br J Clin Pharmacol2007，63，4： | 1 |
| 12 | Rivaroxaban (BAY 59-7939)-anoral,direct factor xa inhibitor-has no clinically relevant interaction with naproxen显示文摘 | Kubitza D Becka M Mueck W | 2007 | Br J Clin Pharmaeol2007，63，4： | 1 |
| 13 | The oral direct factor Xa inhibitor BAY 59-7939 does not prolong the QTc in- terval 显示文摘 | Kubitza D Mueck W Becka M | 2006 | J Clin Pharm2006，46，8： | 1 |
| 14 | Dose-escalation study of the pharmacokinetics and pharmaeodynamics of rivaroxaban in heahhy elderly subjects显示文摘 | Kubitza D Becka M Roth A Mueck W | 2008 | Current Med Res Opin2008，24，： | 1 |
| 15 | Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in healthy subjects显示文摘 | MUECK W BECKA M KUBITZA D | 2007 | Int J Clin Pharmacol Ther2007，45，6： | 1 |
| 16 | Further evidence for direct vascular actions of statins:effect on endothelial nitric oxide synthase and adhesion moldcules显示文摘 | Mueck AO Seeger H Risch M | 2001 | Exp Clin Endocrinol Diabetes2001，109，： | 1 |
| 17 | Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral direct factor Xa inhibitor-in healthy subjects显示文摘 | Mueck W Becka M Kubitza D | 2007 | Int J Clin Pharmacol Ther2007，45，： | 1 |
| 18 | Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban an oral, direct factor Xa inhibitor are not affected by aspirin 显示文摘 | Kubitza D Becka M Mueck W | 2006 | J Clin Pharmacol2006，46，9： | 1 |
| 19 | Rivaroxaban (BAY 59-7939) an oral, direct Factor Xa inhibitor has no clinically relevant interaction with naproxen 显示文摘 | Kubitza D Becka M Mueck W | 2007 | Br J Clin Pharmacol2007，63，4： | 1 |
| 20 | Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor 显示文摘 | Kubitza D Becka M Mueck W | 2010 | Br J Clin Pharmacol2010，70，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员